image description

Tag: Albert Roy

Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-class Lupus Treatment

The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics congratulate Bristol Myers Squibb (BMS) on new positive results from a Phase 2 trial of the investigational agent deucravacitinib as a possible treatment for systemic lupus erythematosus (SLE). Data showed that a significantly higher percentage of patients treated with the study drug met the […] Read More

Thanks to LADA for Major Donation to Research Funding

August 24, 2021 We give a big thank you to the Lupus and Allied Diseases Association, Inc. (LADA) for their generous donation of $120,000 to support research funded by the Lupus Research Alliance.  The funding is specifically directed to Dr. Zahi Touma at University of Toronto for his Modeling Cognitive Impairment project and Dr. Joyce Chang at Boston Children’s […] Read More

Lupus Research Lifted Up in Everyday Health

May 27, 2021 Funding innovative research year-round is the most meaningful way the Lupus Research Alliance Lifts Up Lupus with the promise of better treatments and one day a cure. This excellent article in EVERYDAY HEALTH reports on eight of the most important discoveries in lupus of the past year, virtually all of which got […] Read More

Join LRA March 11 to Learn What’s New in Lupus Nephritis

What’s New in Lupus Nephritis? A Research & Treatment Update A Learn from Lupus Webcast Lupus nephritis is a common and dangerous complication of lupus marked by inflammation that can lead to damage and possible failure of the kidney. While up to half of people with lupus develop lupus nephritis, a new survey by the Lupus […] Read More

Watch Webcast Video: Redefining Lupus Trials Amid COVID-19 and Beyond

Videotape of 8.24.20 Learn from Lupus Zoom Webcast Ensuring the clinical trial process is accommodating for participants has always been the goal. However, COVID-19 has forced industry, research organizations, doctors, and patients to think twice about the process and its impact on high-risk populations including people with lupus who are immunocompromised. In light of COVID-19, […] Read More

Lupus and COVID-19: What You Need to Know – LIVE WEBCAST May 21 at 6 PM ET

Since the arrival of the novel coronavirus, lupus and the most prescribed drug used to treat it – hydroxychloroquine – have been thrust into the public spotlight despite the mounting scientific evidence that drug does not appear to improve clinical outcomes in patients with COVID-19. What has been talked about less is what the impact […] Read More

VALUE Study Results Reported at EULAR

MADRID, Spain. June 13, 2019 – Results of the first clinical trial conducted through the Lupus Research Alliance Lupus Clinical Investigators Network (LuCIN) were presented today at the European Congress of Rheumatology (EULAR) 2019.  The study, called VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool (VALUE),  showed that a custom smartphone app allowed people with lupus […] Read More

Lupus Therapeutics Launches Peer Training Program to Help Patients Benefit from Clinical Trials

NEW YORK, NY. February 1, 2019. Lupus Research Alliance clinical affiliate Lupus Therapeutics launched the Patient Advocates for Lupus Studies (PALS) program with a pilot study to determine its effectiveness in increasing awareness of and participation in lupus clinical trials, particularly among diverse populations.  PALS was formed to address the pressing issue of underrepresentation in clinical studies […] Read More